Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 15/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1450297 | 0.90 | NOTUM (0.62) | NOTUMALDH1A1SMN1; SMN2LMNAPKM | |
| SCHEMBL1165734 | 0.87 | NOTUM (0.60) | NOTUMALDH1A1SMN1; SMN2 | |
| SCHEMBL4805138 | 0.83 | CYP11B1 (0.44) | NOTUMALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL4810394 | 0.83 | KDM4E (0.46) | NOTUMALDH1A1SMN1; SMN2PKM | |
| SCHEMBL4804622 | 0.83 | TSHR (0.46) | NOTUMALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL4859817 | 0.81 | TSHR (0.43) | NOTUMALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4859975 | 0.81 | TSHR (0.47) | NOTUMALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4813456 | 0.80 | LMNA (0.42) | NOTUMALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4802212 | 0.80 | TSHR (0.46) | NOTUMALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL4810771 | 0.79 | TSHR (0.43) | NOTUMALDH1A1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422235-B2 | Sulfonamide derivatives with therapeutic indications | PHARMOS CORPORATION (US) | 2016-08-23 | — | — | US | claimed |
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | PHARMOS CORPORATION | 2010-03-04 | — | — | US | claimed |
| JP-2007518824-A | — | — | 2007-07-12 | — | — | JP | claimed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | claimed |
| CN-1671700-A | Substituted alkylamine derivatives and methods of use | AMGEN INC (US) | 2005-09-21 | — | — | CN | claimed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | claimed |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2023-06-01 | — | — | US | disclosed |
| EP-4143185-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2023-03-08 | — | — | EP | disclosed |
| CN-109311813-B | Palladium-catalyzed meta-C-H functionalized universal ligands | 斯克利普斯研究院 | 2023-02-28 | — | — | CN | disclosed |
| CN-115515953-A | Novel imidazolidinone derivatives as inhibitors of protein kinases, in particular DYRK1A, CLK1 and/or CLK4 | 珀哈制药公司 | 2022-12-23 | — | — | CN | disclosed |
| WO-2021219828-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | PERHA PHARMACEUTICALS (FR) | 2021-11-04 | — | — | WO | disclosed |
| EP-3904354-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | Perha Pharmaceuticals (FR) | 2021-11-03 | — | — | EP | disclosed |
| US-20200369618-A1 | ASYMMETRIC DERIVATIVES OF POLYPHENOLS OF THE DINAPHTHALINE SERIES, PROCESS OF PREPARING AND USE THEREOF | Nearmedic International Limited (CY) | 2020-11-26 | — | — | US | disclosed |
| US-20030216403-A1 | Serine protease inhibitors | TULARIK LIMITED (GB) | 2003-11-20 | — | — | US | disclosed |
| EP-1358184-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | Amgen Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6525069-B1 | Such as N-(t-butyl)-N'-(2-((3-(4-fluorophenyl)methyl)piperi -dinyl)methyl)cyclohexyl)urea; prevention of asthma and other allergic diseases | BRISTOL-MYERS SQUIBB PHARMA CO. | 2003-02-25 | — | — | US | disclosed |
| US-20030018059-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-01-23 | — | — | US | disclosed |
| US-6492400-B1 | SUCH AS N-(2,5-DIFLUOROPHENYL)-N'-(2-((4-(PHENYLMETHYL)-1 -PIPERIDINYL)METHYL)PHENYL)UREA; PREVENTION OF ASTHMA AND OTHER ALLERGIC DISEASES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-6444686-B1 | FOR THE PREVENTION OF ASTHMA AND OTHER ALLERGIC DISEASES. | BRSITOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-03 | — | — | US | disclosed |
| WO-2002066470-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056528-A1 | SULFONAMIDE DERIVATIVES WITH THERAPEUTIC INDICATIONS | SULT2A1, STS, SULT1A1 | NOTUM 2599/4885ALDH1A1 245/4885SMN1; SMN2 221/4885 |
| US-20200369618-A1 | ASYMMETRIC DERIVATIVES OF POLYPHENOLS OF THE DINAPHTHALINE SERIES, PROCESS OF PREPARING AND USE THEREOF | DNM2, DNM1, MAVS | NOTUM 1677/4885ALDH1A1 859/4885SMN1; SMN2 2649/4885 |
| US-20030216403-A1 | Serine protease inhibitors | SERPINB1, SERPINE1, PRSS1 | NOTUM 1129/4885ALDH1A1 1913/4885SMN1; SMN2 3179/4885 |
| US-20030018059-A1 | Serine protease inhibitors | TPSAB1, PRSS1, SERPINB1 | NOTUM 782/4885ALDH1A1 1335/4885SMN1; SMN2 3761/4885 |
| US-20230167104-A1 | NEW IMIDAZOLONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES IN PARTICULAR DYRK1A, CLK1 AND/OR CLK4 | CLK1, CLK2, CLK3 | NOTUM 4634/4885ALDH1A1 2647/4885SMN1; SMN2 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.